Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives

DOI: https://doi.org/10.1186/s40035-025-00465-w

Key Discussion Points:

1. Overview of Current Landscape

- Three FDA-approved second-generation antibodies: Aducanumab, Lecanemab, Donanemab

- Lecanemab recently received traditional FDA approval

- Represents validation of amyloid cascade hypothesis

2. Individual Antibody Profiles:

Aducanumab

- Derived from memory B cells of both healthy and cognitively impaired individuals

- Targets amyloid beta plaques (amino acids 3-7)

- Shows dose-dependent reduction in amyloid beta

- Notable occurrence of ARIA side effects

Lecanemab

- Derived from mouse antibody MA158

- Targets amyloid beta protofibrils (amino acids 1-16 and 21-29)

- ClarityAD trial showed slowing of cognitive decline

- Affects both amyloid beta and phosphorylated tau levels

Donanemab

- Targets N-terminal pyroglutamate of amyloid beta

- Trailblazer ALZ trials showed significant amyloid reduction

- Initially denied accelerated approval due to limited patient data

- Later trials showed more positive findings

Gantenerumab

- Engineered using Hucal phage display technology

- Targets amyloid beta fibrils (amino acids 3-11 and 18-27)

- Mixed results: Early trials showed amyloid reduction but larger Graduate I/II trials didn't show significant cognitive improvement

- Dosing and delivery methods may have affected results

3. Key Challenges:

ARIA (Amyloid-Related Imaging Abnormalities)

- Manifests as edema (ARIA-E) or hemorrhage (ARIA-H)

- Involves complement cascade and FCR-mediated signaling

- Major safety concern requiring careful monitoring

Blood-Brain Barrier

- Limits antibody penetration

- Requires high doses which can increase ARIA risk

4. Future Directions:

Innovative Strategies:

- Antibody Drug Conjugates (ADCs) combining antibodies with targeted payloads

- Targeted Protein Degradation (TPD) approaches

- Modified antibodies like α Aβ-Gas6 fusion protein

- Personalized therapy approaches based on biomarkers

- Combination therapies targeting multiple disease aspects

Biomarker Development:

- MicroRNA-based early detection

- Blood-based testing potential

- Importance of early intervention

Conclusion:

The field shows promise but requires continued research to optimize safety and efficacy. Future success likely lies in combination approaches and personalized treatment strategies.